Clinical Study
|
Open Access
Featured
-
-
Short Communication
| Open AccessCross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
- C Oliveras-Ferraros
- , S Cufí
- & J A Menendez
-
Translational Therapeutics
| Open AccessNegative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
- L G Feun
- , A Marini
- & N Savaraj
-
Molecular Diagnostics
| Open AccessNT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
- H Wang
- , S Lee
- & T Crook
-
Translational Therapeutics
| Open AccessDissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
- K Henare
- , L Wang
- & L-M Ching
-
Short Communication
| Open AccessSkin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening
- A Waldmann
- , S Nolte
- & A Katalinic
-
Molecular Diagnostics
| Open AccessMutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
- K Sakaizawa
- , Y Goto
- & R Okuyama
-
Translational Therapeutics
| Open AccessSigma-2 ligands induce tumour cell death by multiple signalling pathways
- C Zeng
- , J Rothfuss
- & R H Mach
-
Molecular Diagnostics
| Open AccessDifferential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors
- Y Xu
- , T Brenn
- & D W Melton
-
Molecular Diagnostics
| Open AccessHigh basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives
- Z Janjetovic
- , A A Brozyna
- & A T Slominski
-
Molecular Diagnostics
| Open AccessTYRP1 mRNA expression in melanoma metastases correlates with clinical outcome
- F Journe
- , H Id Boufker
- & G Ghanem
-
Molecular Diagnostics
| Open AccessHost-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production
- H Fukuda
- , S Mochizuki
- & Y Okada
-
Translational Therapeutics
| Open AccessOverexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
- M Nagata
- , H Nakayama
- & M Shinohara
-
Molecular Diagnostics
| Open AccessExpression and functional role of CRIPTO-1 in cutaneous melanoma
- A De Luca
- , L Lamura
- & N Normanno
-
Molecular Diagnostics
| Open AccessmiR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions
- V Grignol
- , E T Fairchild
- & W E Carson III
-
Molecular Diagnostics
| Open AccessTumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma
- N Nohata
- , T Hanazawa
- & N Seki
-
Epidemiology
| Open AccessSecond cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study
- J A Royle
- , P D Baade
- & L Fritschi
-
Translational Therapeutics
| Open AccessImmune activation by combination human lymphokine-activated killer and dendritic cell therapy
- E J West
- , K J Scott
- & A A Melcher
-
Molecular Diagnostics
| Open AccessExpression of laminin 5-γ2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion
- H Hamasaki
- , K Koga
- & K Nabeshima
-
Clinical Study
| Open AccessInhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
- H A Tawbi
- , L Villaruz
- & J M Kirkwood
-
Clinical Study
| Open AccessA randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
- S O'Day
- , A Pavlick
- & P Ho
-
Clinical Study
| Open AccessSorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
- T Eisen
- , R Marais
- & M E Gore
-
Genetics and Genomics
| Open AccessFunctional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma
- G Gremel
- , D Ryan
- & W M Gallagher
-
Letter to the Editor
| Open AccessStability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
- L Sigalotti
- , E Fratta
- & M Maio
-
Molecular Diagnostics
| Open AccessCTGF is overexpressed in malignant melanoma and promotes cell invasion and migration
- S Braig
- , S Wallner
- & A-K Bosserhoff
-
Molecular Diagnostics
| Open AccessHOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
- C deBlacam
- , C Byrne
- & L S Young
-
Clinical Study
| Open AccessCentral nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
- V Chiarion-Sileni
- , M Guida
- & G L De Salvo
-
Molecular Diagnostics
| Open AccessCo-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis
- J Wood
- , M Pring
- & A Hague
-
Molecular Diagnostics
| Open AccessHigh-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients
- M Reuschenbach
- , T Tran
- & C Sommerer
-
Translational Therapeutics
| Open AccessA chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
- A Palumbo
- , F Hauler
- & D Neri
-
Molecular Diagnostics
| Open AccessUpregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma
- Y H Liao
- , S M Hsu
- & P H Huang
-
Clinical Study
| Open AccessA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
- O A Khan
- , M Gore
- & M R Middleton
-
Molecular Diagnostics
| Open AccessDifferent miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study
- C B Lajer
- , F C Nielsen
- & C von Buchwald
-
Translational Therapeutics
| Open AccessTemsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- Y Wang
- , X-Y Wang
- & H L Kim
-
Translational Therapeutics
| Open AccessDevelopment and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
- M Z Mohammed
- , V N Vyjayanti
- & S Madhusudan
-
Molecular Diagnostics
| Open AccessPolyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
- J Lin
- , Y Goto
- & M Takata
-
Molecular Diagnostics
| Open AccessGene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion
- O Berthier-Vergnes
- , M El Kharbili
- & J Lamartine
-
Clinical Study
| Open AccessSkin cancer screening behaviours among individuals with a strong family history of malignant melanoma
- N A Kasparian
- , J K McLoone
- & G J Mann
-
Translational Therapeutics
| Open AccessElastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase
- J Devy
- , L Duca
- & L Debelle
-
Clinical Study
| Open AccessPhase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
- R C DeConti
- , A P Algazi
- & A I Daud
-
Molecular Diagnostics
| Open AccessMelanoma sentinel node biopsy and prediction models for relapse and overall survival
- A Mitra
- , C Conway
- & J A Newton-Bishop
-
Translational Therapeutics
| Open AccessMGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
- J C Hassel
- , A Sucker
- & D Schadendorf
-
Translational Therapeutics
| Open AccessNutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
- A K Arya
- , A El-Fert
- & M T Boyd
-
Short Communication
| Open AccessSkin cancers associated with autoimmune conditions among elderly adults
- E Lanoy
- & E A Engels
-
Translational Therapeutics
| Open AccessRecovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- K H T Paraiso
- , I V Fedorenko
- & K S M Smalley
-
Editorial
| Open AccessIs GP-led follow-up feasible?
- A B Francken
- , J W Hoekstra-Weebers
- & H J Hoekstra
-
Clinical Study
| Open AccessPatient satisfaction with GP-led melanoma follow-up: a randomised controlled trial
- P Murchie
- , M C Nicolson
- & N C Campbell
-
Translational Therapeutics
| Open AccessNovel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
- D Lecis
- , C Drago
- & D Delia
-
Epidemiology
| Open AccessTrends in skin cancer incidence by socioeconomic position in Scotland, 1978–2004
- V R Doherty
- , D H Brewster
- & D Gorman
-
Clinical Study
| Open AccessClinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
- D Handolias
- , A L Hamilton
- & G A McArthur